Anal Adenocarcinoma
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays (NCT02407561) | Castle Biosciences Incorporated | 2015-02-01 |
Track Anal Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.